Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: metformin hydrochloride, metformin | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1191
Sealed predictions
- GPD2 in dopamine neurons, braak+0.28 (p 0.471) → +0.27 (p 0.485)receipt 1198
Swarm cases
receipt 1198: GPD2 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.888, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.09, sign flips 5; without severely affected donors -0.04 (p 0.888, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GPD2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts